|
|
News Breaks | | | | January 31, 2013 | | 06:12 EDT |  | BAYRY | France to halt sales of Bayer's acne drug and its generics, WSJ reports
France's National Agency for the Safety of Drugs and Health Products is taking steps to stop sales of an acne treatment made by Bayer (BAYRY) that is widely used as a contraceptive, after the drug was linked to four deaths over the past 25 years, reports the Wall Street Journal. The hormonal treatment Diane 35, along with its generic equivalents, are used by more than 300,000 women in France. The drug is sold in 116 countries and generated sales of $246M for Bayer in 2011.Reference Link | |
|
News For BAYRY From The Last 14 Days Check below for free stories on BAYRY the last two weeks. |
|
|
| June 7, 2013 | | 10:11 EDT |  | BAYRY | On The Fly: Analyst Upgrade Summary
 Subscribe for More Information | | | 05:38 EDT | | BAYRY | Bayer upgraded to Outperform from Neutral at Exane BNP Paribas
Subscribe for More Information | | | June 6, 2013 | | 05:49 EDT |  | BAYRY | Regeneron, Bayer reports positive Phase 3 results for Eylea
Regeneron Pharmaceuticals (REGN) and Bayer HealthCare (BAYRY) announced positive top-line results for EYLEA Injection from the Phase 3 MYRROR study in myopic choroidal neovascularization. In this trial, patients receiving EYLEA at an initial dose of 2 milligrams, followed by treatment on an as-needed basis, had a mean improvement in best-corrected visual acuity from baseline at week 24 of 12.1 letters, compared to a loss of 2.0 letters in patients receiving sham injections. The most common adverse events observed in the MYRROR trial that occurred with a frequency of 2% or more were conjunctival hemorrhage, dry eye, eye pain, headache and nasopharyngitis. | | | June 5, 2013 | | 07:52 EDT | | BAYRY | Bayer acquires majority interest in Conceptus with 96.4% shares tendered
Subscribe for More Information | |
|
|
|
|
|
|
